Literature DB >> 18186958

The evolving role of interventional pulmonary in the interdisciplinary approach to the staging and management of lung cancer. Part III: diagnosis and management of malignant pleural effusions.

Ken Y Yoneda1, Praveen N Mathur, Stefano Gasparini.   

Abstract

The diagnosis and management of a malignant pleural effusion can be one of the most vexing problems faced by physicians and their patients. Lung cancer is the most common primary tumor of origin with a prognosis that is limited, but variable and correlated with performance status (PS). Therefore, with a poor PS and known advanced lung cancer, establishing whether or not an effusion is malignant might not be necessary. Conversely, identifiable subsets of patients will have a much better survival, and establishing a definitive diagnosis could be of critical importance. In the great majority of cases, a diagnosis can be determined by serial thoracenteses with or without closed pleural biopsy. However, thoracoscopy is increasingly being utilized and can expedite the workup by obviating the need for repeated thoracenteses and/or closed pleural biopsy, while in the same setting providing definitive palliative treatment. Although studies comparing diagnostic and treatment strategies are limited, we will present the available data with the intention of providing the practicing oncologist with a practical strategy for the diagnosis and management of malignant pleural effusions due to lung cancer. The interventional pulmonologist can play an important role from diagnosis to palliation, greatly facilitating the care of patients with malignant pleural effusions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18186958     DOI: 10.3816/CLC.2007.n.040

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  3 in total

Review 1.  Symptomatic Fluid Drainage: Tunneled Peritoneal and Pleural Catheters.

Authors:  Tony Ha; David C Madoff; David Li
Journal:  Semin Intervent Radiol       Date:  2017-12-14       Impact factor: 1.513

2.  Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions.

Authors:  Cui-Qing Bai; Yan-Wen Yao; Chun-Hua Liu; He Zhang; Xiao-Bing Xu; Jun-Li Zeng; Wen-Jun Liang; Wen Yang; Yong Song
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

Review 3.  International consensus on severe lung cancer-the first edition.

Authors:  Chengzhi Zhou; Shiyue Li; Jun Liu; Qian Chu; Liyun Miao; Linbo Cai; Xiuyu Cai; Yu Chen; Fei Cui; Yuchao Dong; Wen Dong; Wenfeng Fang; Yong He; Weifeng Li; Min Li; Wenhua Liang; Gen Lin; Jie Lin; Xinqing Lin; Hongbing Liu; Ming Liu; Xinlin Mu; Yi Hu; Jie Hu; Yang Jin; Ziming Li; Yinyin Qin; Shengxiang Ren; Gengyun Sun; Yihong Shen; Chunxia Su; Kejing Tang; Lin Wu; Mengzhao Wang; Huijuan Wang; Kai Wang; Yuehong Wang; Ping Wang; Hongmei Wang; Qi Wang; Zhijie Wang; Xiaohong Xie; Zhanhong Xie; Xin Xu; Fei Xu; Meng Yang; Boyan Yang; Xiangjun Yi; Xiaoqun Ye; Feng Ye; Zongyang Yu; Dongsheng Yue; Bicheng Zhang; Jian Zhang; Jianqing Zhang; Xiaoju Zhang; Wei Zhang; Wei Zhao; Bo Zhu; Zhengfei Zhu; Wenzhao Zhong; Chunxue Bai; Liangan Chen; Baohui Han; Chengping Hu; Shun Lu; Weimin Li; Yong Song; Jie Wang; Caicun Zhou; Jianying Zhou; Yanbin Zhou; Yuichi Saito; Yoshinobu Ichiki; Hitoshi Igai; Satoshi Watanabe; Sara Bravaccini; Alfonso Fiorelli; Francesco Petrella; Takeo Nakada; Piergiorgio Solli; Nikolaos Tsoukalas; Yuki Kataoka; Taichiro Goto; Rossana Berardi; Jianxing He; Nanshan Zhong
Journal:  Transl Lung Cancer Res       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.